Who
Hal Barron
Director
Company insider
Files Form 4 as: Director, Quantinuum; Director, Juno Therapeutics; Director, Alexza Pharmaceuticals; SVP - Development & Cmo, Genentech.
In numbers
- Trades disclosed
- 37
- Buys
- 2
- Sells
- 0
- Bought
- $32.4M
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 22 Jan 2009
- Last trade
- 5 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 8 Jun 2026 | QNT QuantinuumIT Services & Consulting | SEC FORM 4 Bought | $15.0M250,000 at $60.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | QNT QuantinuumIT Services & Consulting | SEC FORM 4 Bought | $15.0M250,000 at $60.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | QNT QuantinuumIT Services & Consulting | SEC FORM 4 Code A | —5,833 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | QNT QuantinuumIT Services & Consulting | SEC FORM 4 Code A | —5,833 at $0.00 | filing |
| 5 Mar 2018filed 7 Mar 2018 | Juno Therapeutics | SEC FORM 4 Code U | $8.7M100,000 at $87.00 | filing |
| 5 Mar 2018filed 7 Mar 2018 | Juno Therapeutics | SEC FORM 4 Code D | $329K3,780 at $87.00 | filing |
| 5 Mar 2018filed 7 Mar 2018 | Juno Therapeuticsoption or derivative | SEC FORM 4 Code D | $6.0M75,000 at $80.64 | filing |
| 5 Mar 2018filed 7 Mar 2018 | Juno Therapeuticsoption or derivative | SEC FORM 4 Code D | $324K12,000 at $27.00 | filing |
| 5 Mar 2018filed 7 Mar 2018 | Juno Therapeuticsoption or derivative | SEC FORM 4 Code D | $535K12,000 at $44.60 | filing |
| 5 Mar 2018filed 7 Mar 2018 | Juno Therapeuticsoption or derivative | SEC FORM 4 Code D | $765K12,000 at $63.71 | filing |
| 5 Jan 2018filed 9 Jan 2018 | Juno Therapeutics | SEC FORM 4 Code A | —336 at $0.00 | filing |
| 5 Oct 2017filed 6 Oct 2017 | Juno Therapeutics | SEC FORM 4 Code A | —361 at $0.00 | filing |
| 5 Jul 2017filed 7 Jul 2017 | Juno Therapeutics | SEC FORM 4 Code A | —516 at $0.00 | filing |
| 16 Jun 2017filed 19 Jun 2017 | Juno Therapeuticsoption or derivative | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 5 Apr 2017filed 6 Apr 2017 | Juno Therapeutics | SEC FORM 4 Code A | —698 at $0.00 | filing |
| 5 Jan 2017filed 9 Jan 2017 | Juno Therapeutics | SEC FORM 4 Code A | —768 at $0.00 | filing |
| 5 Oct 2016filed 17 Oct 2016 | Juno Therapeutics | SEC FORM 4 Code A | —438 at $0.00 | filing |
| 5 Jul 2016filed 5 Jul 2016 | Juno Therapeutics | SEC FORM 4 Code A | —328 at $0.00 | filing |
| 17 Jun 2016filed 21 Jun 2016 | Juno Therapeuticsoption or derivative | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 5 Apr 2016filed 7 Apr 2016 | Juno Therapeutics | SEC FORM 4 Code A | —335 at $0.00 | filing |
News
Quantinuum (NASDAQ:QNT) Shares Climb 7.7% – Time to Buy?QNT · themarketsdaily.com · 21 Oct 2026Nvidia's $1B Research Commitment Puts IonQ (NYSE: IONQ), Quantinuum (NYSE: QNT), And Rigetti (NASDAQ: RGTI) Quantum Stocks In FocusQNT · foreignpolicyjournal.com · 10 Oct 2026Quantinuum (NASDAQ:QNT) Hits New 52-Week Low – Here's What HappenedQNT · tickerreport.com · 9 Oct 2026
0 headlines in the last 90 days name Hal Barron; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.
Sectors
Related people
Nobody else traded the same names lately.